Brought to you by 
Molecular Templates finds new investor in $8.5mm Series C; round extended by $3.5mm
15 Sep 2014
Executive Summary
Molecular Templates Inc. (developing next-generation antibody-drug conjugates for cancer) raised $8.5mm through its Series C round. New investor Excel Venture Management led (and takes two seats on the board), and was joined by returning backer Santé Ventures. The company also announced receipt of a $10.6mm grant from the Cancer Prevention & Research Institute of Texas last year. Funds will go towards upcoming Phase I trials of lead compound MT3724, an engineered toxin body for B-cell lymphomas.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Molecular Templates finds new investor in $8.5mm Series C; round extended by $3.5mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice